CLINICIAN PATHWAYS

DARC (Detection of Apoptosing Retinal Cells) is a groundbreaking biomarker that integrates into clinical pathways to improve decision-making in Wet AMD treatment. By identifying non-responders early, DARC enables tailored treatment plans, reducing unnecessary treatments and preserving vision.

Early Detection: DARC can predict the development of Wet AMD up to 36 months before it’s visible on OCT, allowing for earlier intervention.

1. Personalized Treatment: Quickly identify non-responders to first-line treatments like Avastin, enabling a faster switch to more effective options.

2. Improved Outcomes: DARC reduces treatment timelines, cutting down on the number of doses needed and potentially saving vision in challenging cases.

Clinical Impact: In best-case scenarios, DARC has shown to reduce treatment duration from 10 to 3 months, while in worst-case scenarios, it can shorten ineffective treatment periods by up to 24 months.

Proven Research: Published Phase IIa trials demonstrate that a high DARC count at the macula strongly correlates with future Wet AMD, reinforcing its predictive power.

WHY INCORPORATE DARC IN YOUR PRACTICE?

Incorporating the innovative DARC technology into your clinical practice can significantly streamline the management of Wet AMD, ultimately offering better patient outcomes and reducing the overall burden on both patients and healthcare providers alike. By utilizing DARC, you can enhance the precision of your diagnostics, leading to more effective treatment strategies that contribute to improved quality of life for those affected by this condition.